BBWP
JAZZ icon

Beacon Bridge Wealth Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Beacon Bridge Wealth Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,651
Closed -$218K – 101
2025
Q3 		$218K Buy
+1,651
New +$198K 0.08% 86

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Beacon Bridge Wealth Partners's JAZZ Position: Q4 2025 in Review

Beacon Bridge Wealth Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2025, closing a stake of 1,651 shares — an estimated $218K sold.

Beacon Bridge Wealth Partners first reported a position in JAZZ in Q3 2025 and held it in 1 quarter. The position peaked at $218K in Q3 2025. 574 funds tracked by Wall St. Rank hold JAZZ as of Q4 2025.

  • Beacon Bridge Wealth Partners reported no remaining Jazz Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Beacon Bridge Wealth Partners sold 1,651 Jazz Pharmaceuticals shares in Q4 2025, an estimated $218K.
  • Beacon Bridge Wealth Partners first reported a position in Jazz Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Beacon Bridge Wealth Partners's Jazz Pharmaceuticals position peaked at $218K in Q3 2025.
  • 574 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2025.

Based on Beacon Bridge Wealth Partners's 13F filing for Q4 2025, filed 27 Jan 2026.